Jun 7, 2021 - Health

Biogen is banking on aducanumab

Tecfidera as a share of Biogen revenue
Data: Company filings; Chart: Danielle Alberti/Axios

Multiple sclerosis drug Tecfidera has propped up Biogen for the past eight years, representing more than a third of the company's sales. But that revenue wave is coming to an end after generic versions of the pill entered the U.S. market last year.

Between the lines: Biogen is banking on federal approval of its Alzheimer's drug, aducanumab, to boost its financial future and offset the decline of Tecfidera.

By the numbers: Market analysts estimate Biogen could price aducanumab as high as $50,000 per year of treatment, if it’s approved. Independent experts have said that price is too high considering the clinical trial data don't prove the drug is effective in combating the brain disorder.

  • Even if only a small portion of the 6 million Alzheimer's patients are able to obtain the drug, Biogen would net billions of dollars in new sales annually.
Go deeper